Nexalin Technology Inc (NXL)
Nexalin Technology Inc. is a healthcare company focused on medical device development, with an emphasis on neurostimulation products for mental health applications. The company designs devices intended for use in the United States and China, including Generation 1, a bioelectronic medical device used in treatment settings for anxiety, insomnia, and depression without drugs or psychotherapy. It also develops Generation 2 and Generation 3 headset devices aimed at conditions such as depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, chronic pain, Alzheimer’s disease, and dementia. Nexalin Technology is headquartered in Houston, Texas. The listed security is common stock on NASDAQ.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NXL
|
$6.18
|
26.0% Upside
|
Undervalued
|
$60 1,124.5% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
December 2, 2026
|
2.4x
|
16.6x
|
3.599 M
|
2.594 M
|
0.0%
|
72.2%
|
-85.4
|
68.7%
|
